Group 1 - Ailux, a subsidiary of Crystal Tech Holdings, has entered into a strategic collaboration with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The collaboration allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis [1] - The total potential value of the collaboration, including development, regulatory, and commercial milestone payments, could reach up to $345 million [1] Group 2 - Ailux is an exclusive biopharmaceutical innovation platform of Crystal Tech Holdings, utilizing AI-driven solutions to develop advanced biotherapies [2] - Ailux combines proprietary computational models with cutting-edge wet lab capabilities to tackle traditionally undruggable targets and design biologics with innovative drug potential [2] - Ailux has a global team of over 100 people working with leading biopharmaceutical companies to translate advanced science into transformative medicines [2]
晶泰控股(02228)子公司AILUX宣布与礼来战略合作赋能(AI驱动)双特异性抗体开发